blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1586587

EP1586587 - Compositions and methods for detecting angiogenesis [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  29.12.2006
Database last updated on 15.06.2024
Most recent event   Tooltip22.08.2008Change - representativepublished on 24.09.2008  [2008/39]
Applicant(s)For all designated states
Exonhit Therapeutics SA
26, rue Brunel
75017 Paris / FR
[2005/42]
Inventor(s)01 / Kearsey, Jonathan
Résidence Orée de Senart, Bâtiment du Bellay 1
91210 Draveil / FR
 [2005/42]
Representative(s)Becker, Philippe, et al
Cabinet Becker & Associés
25 Rue Louis Le Grand
75002 Paris / FR
[N/P]
Former [2008/39]Becker, Philippe, et al
Cabinet Becker & Associés 25, rue Louis Le Grand
75002 Paris / FR
Former [2005/42]Becker, Philippe, et al
Cabinet BECKER & ASSOCIES 25, rue Louis Le Grand
75002 Paris / FR
Application number, filing date04291020.816.04.2004
[2005/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1586587
Date:19.10.2005
Language:EN
[2005/42]
Search report(s)(Supplementary) European search report - dispatched on:EP07.01.2005
ClassificationIPC:C07K14/81, C07K16/38, C12Q1/68, G01N33/574, G01N33/68
[2005/42]
CPC:
C07K14/8114 (EP); C12Q1/6886 (EP); G01N33/574 (EP);
G01N33/68 (EP); C12Q2600/112 (EP); C12Q2600/136 (EP);
C12Q2600/158 (EP); G01N2333/8114 (EP) (-)
Designated contracting states[2006/26]
Former [2005/42]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IT,  LI,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Zusammensetzungen und Verfahren zum Nachweis der Angiogenese[2005/42]
English:Compositions and methods for detecting angiogenesis[2005/42]
French:Préparations et méthodes pour détecter l'angiogenèse[2005/42]
Examination procedure20.04.2006Application deemed to be withdrawn, date of legal effect  [2007/05]
18.08.2006Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2007/05]
Fees paidPenalty fee
Penalty fee Rule 85a EPC 1973
29.05.2006AT   M01   Not yet paid
29.05.2006BE   M01   Not yet paid
29.05.2006BG   M01   Not yet paid
29.05.2006CH   M01   Not yet paid
29.05.2006CY   M01   Not yet paid
29.05.2006CZ   M01   Not yet paid
29.05.2006DE   M01   Not yet paid
29.05.2006DK   M01   Not yet paid
29.05.2006EE   M01   Not yet paid
29.05.2006ES   M01   Not yet paid
29.05.2006FI   M01   Not yet paid
29.05.2006FR   M01   Not yet paid
29.05.2006GB   M01   Not yet paid
29.05.2006GR   M01   Not yet paid
29.05.2006HU   M01   Not yet paid
29.05.2006IE   M01   Not yet paid
29.05.2006IT   M01   Not yet paid
29.05.2006LU   M01   Not yet paid
29.05.2006MC   M01   Not yet paid
29.05.2006NL   M01   Not yet paid
29.05.2006PL   M01   Not yet paid
29.05.2006PT   M01   Not yet paid
29.05.2006RO   M01   Not yet paid
29.05.2006SE   M01   Not yet paid
29.05.2006SI   M01   Not yet paid
29.05.2006SK   M01   Not yet paid
29.05.2006TR   M01   Not yet paid
Penalty fee Rule 85b EPC 1973
29.05.2006M01   Not yet paid
Additional fee for renewal fee
30.04.200603   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[AD]WO9946403  (EXONHIT THERAPEUTICS SA [FR], et al) [AD] 1-22 * the whole document *;
 [XY]WO03046180  (GENSET SA [FR], et al) [X] 1-5,7-18,21,22 * page 127 - page 130, paragraph 2 * * page 132 - page 133 * * SEQ ID NO:27 (DNA) and SEQ ID NO:28 (protein) : HAI-2 with exon 2 deleted * [Y] 6;
 [Y]US6583108  (TAMBURINI PAUL P [US], et al) [Y] 6 * abstract * * column 15, line 22 - line 33 * * column 16, line 18 - line 46 * * column 18, line 41 - column 19, line 3 *;
 [X]EP1374891  (BAYER AG [DE]) [X] 1-5 * paragraph [0053] *;
 [XY]WO2004023973  (INCYTE CORP [US], et al) [X] 1-5,7-16,21,22 * claims 1,4-6,13,14,27,28 * * page 74, line 16 - line 32 * * page 105 - page 112, line 25 * * page 143, line 8 - line 11 * * page 149, line 18 - page 150, line 16 * * page 154, line 24 - page 156, line 16 * * tables 1-4 * * SEQ ID NO: 2118 (DNA) and SEQ ID NO: 4840 (protein) : HAI-2 with exon 3 deleted * [Y] 6;
 [X]  - ITOH H. ET AL., "Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human.", BIOCHEM. BIOPHYS. RES. COMM., (1999), vol. 255, pages 740 - 748, XP002311333 [X] 12-16 * abstract * * page 744 * * page 745, column 1 * * figures 1-5 *

DOI:   http://dx.doi.org/10.1006/bbrc.1999.0268
 [AD]  - KAWAGUCHI T. ET AL., "Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor.", J. BIOL. CHEM., (19971031), vol. 272, no. 44, pages 27558 - 27564, XP002311334 [AD] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.272.44.27558
 [A]  - MARLOR C.W. ET AL., "identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains.", J. BIOL. CHEM., (19970502), vol. 272, no. 18, pages 12202 - 12208, XP001149667 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.272.18.12202
 [A]  - BRACCO L. ET AL., "The relevance of alternative RNA splicing to pharmacogenomics.", TRENDS BIOTECHNOL., (200308), vol. 21, no. 8, pages 346 - 353, XP004442025 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0167-7799(03)00146-X
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.